VACCINEX INC by Vaccinex, Inc. Financials - Benzinga

VACCINEX INC by Vaccinex, Inc.

VCNXOTCPK

Trade with Public

Trade with Public

$1.41

At close: Dec 31, 4:00 PM EST

$0.9480

-0.46-32.77%

After Hours: Jan 2, 8:06 AM EST

Overview News Earnings Forecast EventsFinancialsSentiment Ownership Compare

VACCINEX INC by Vaccinex, Inc. Financials

VACCINEX INC by Vaccinex, Inc. (VCNX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Crude Oil Down Over 1%; US Industrial Production Declines In November

Avi Kapoor

PRO
Vaccinex Q3 EPS $(2.83) vs $(15.25) YoY, Revenue $52K vs $20K YoY; Cash, Cash Equivalents And Marketable Securities As Of Sept. 30 Were $2.9M

Benzinga Newsdesk

PRO
Vaccinex Q1 EPS $(2.94), Sales $104.00K Down From $550.00K YoY

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(2.94) per share. The company reported $104.00 thousand in sales this quarter. This is a 81.09 percent decrease over sales of $550.00 thousand the same period last

Benzinga Newsdesk

PRO
Vaccinex Q4 EPS $(0.33) Up From $(23.10) YoY

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(0.33) per share. This is a 98.57 percent increase over losses of $(23.10) per share from the same period last year.

Benzinga Newsdesk

PRO
Vaccinex Expects Topline Data For Phase 1/2a Randomized SIGNAL-AD Study Of Pepinemab For Alzheimer's Disease In Q3 2024

Benzinga Newsdesk

PRO
Vaccinex FY23 EPS $(43.68) Up From $(98.05) YoY, Revenue $570K Up From $275K YoY

Benzinga Newsdesk